Technology leader in lipedema treatment and regenerative medicine
Schwerin and Frankfurt am Main, February 10, 2022
Funds advised by PREMIUM Equity Partners, Frankfurt am Main, have acquired Human Med AG, headquartered in Schwerin. Human Med AG is a leading global manufacturer of medical devices for patented waterjet-assisted liposuction (WAL) applied, among others, to the treatment of lipedema and in the regenerative medicine sector. Human Med employs a permanent staff of 56 employees. In addition to device manufacturing, Human Med produces the related consumables and sterile disposable equipment in its own state-of-the-art clean room production facility built to the latest standards.
The chronic and progressive clinical picture of lipedema describes a fat distribution disorder of a yet unknown cause affecting millions of women in Germany alone and can ultimately only be treated effectively by surgical intervention. WAL technology is the gentlest type of liposuction as the surrounding connective tissue, nerves and blood vessels remain virtually intact. As a result, the fat cells remain highly vital and can be reused as needed for homologous and regenerative applications with outstanding results. Controlled studies have shown that due to the extremely high vitality of the fat cells, most of the injected fat tissue is retained and grows in the recipient area. Such autologous fat thus provides the basis for numerous subsequent applications in reconstructive medicine, for example, in the field of breast reconstruction and or treatment of chronic wounds.
Thanks to its particularly gentle, low-pain, yet time-efficient process and the quality of the harvested fat cells, the WAL technique is widely popular among surgeons as well as patients worldwide.
PREMIUM is acquiring Human Med from the existing shareholders as part of a succession solution. The CEO Bernd Lindner will remain active in the company and intends to support its further development in the medium term as an advisory board member: “As a shareholder of Human Med AG, I am delighted to have found in PREMIUM Equity Partners the right partner to drive growth with a unique, innovative product portfolio. The professional and trustful cooperation with PREMIUM has convinced me and the other shareholders that we will engage with the ideal ally to continue to shape the future international development of the company. We are convinced of our synergies and, consequently, view the coming years with great optimism – I look forward to our future close collaboration.”
Pieter van Halem, Managing Partner of PREMIUM, added: “With its patented technology Human Med has been operating in various growth markets. In the past years, the company could gain large popularity among physicians and patients with the WAL procedure, especially in the European regions. Together with the management, we want to further pursue this development with great energy and exploit the yet untapped economic resources in the field of regenerative medicine.”
About PREMIUM Equity Partners
PREMIUM Equity Partners is an investment company founded in 2011 with a focus on strong niche companies in the DACH region with revenues between EUR 10 million and EUR 50 million. PREMIUM invests capital in the context of growth financing, succession solutions and spin-offs. In each investment, PREMIUM combines its many years of transaction and financing experience with the industry know-how of its industrial partners. This is PREMIUM’s ninth corporate acquisition.
The investment by PREMIUM Mittelstand Fund II GmbH & Co. KG benefits from the financial support of the European Union under the European Fund for Strategic Investments (“EFSI”). The purpose of the EFSI is to support the financing and implementation of economically viable investments in the European Union and ensure improved access to finance.
More information: www.premium-equity.de
Contact Human Med
Human Med AG
T: +49 385 395 70-0
Contact PREMIUM Equity Partners
Pieter van Halem
PREMIUM Equity Partners GmbH
60325 Frankfurt am Main
T: +49 69 677 01 677 0